From: Serum KL-6 is a predictor of outcome in pulmonary alveolar proteinosis
 | KL-6 <1526 U/mL | KL-6 ≥1526 U/mL | p |
---|---|---|---|
(N or mean ± SE) | (N or mean ± SE) | ||
Gender (M/F) | 9/10 | 9/5 | ns* |
Age (yrs) | 52±10 | 46±11 | ns** |
Smoking history (yes/no) | 15/4 | 12/2 | ns* |
Clinical course | Â | Â | Â |
  -PAP-related death (yes/no) | 0/19 | 2/12 | ns* |
  -disease progression (yes/no) | 3/16 | 13/1 | <0.0001* |
Treatment (yes/no) | 6/13 | 12/2 | 0.03* |
  -cumulative number of WLL | 3.5±3 | 7±6.5 | 0.06 |
PaO2 (mmHg) | 78±14 | 66±12 | 0.012** |
A-aDO2 (mmHg) | 31±12 | 42±14 | 0.023** |
VC (% pred) | 88±15 | 72±14 | 0.002** |
FEV1 (% pred) | 81±15 | 67±14 | 0.009** |
TLC (% pred) | 86±17 | 72±16 | 0.017** |
DLCO (% pred) | 70±15 | 42±12 | <0.0001** |
GM-CSF autoantibody (μg/mL) | 44±19 | 55±13 | ns** |
KL-6 (U/mL) | 930±352 | 3934±1756 | <0.0001** |
LDH (IU/L) | 244±78 | 327±109 | ns** |
CEA (ng/mL) | 5.5±3.8 | 7.5±6 | ns** |